Applied BioCodeTPE:6598 74 PS Ratio is 4.93 as of Jul. 12, 2026, which is 30% below its 10-year median of 7.07. GuruFocus rates TPE:6598 with a GF Score™ of 74/100 and a GF Value™ of NT$23.34 (Fairly Valued). The stock has 6 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Applied BioCode ranks worse than 67.95% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Applied BioCode's share price is NT$22.85.
Applied BioCode's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$4.64. Hence, Applied BioCode's PS Ratio for today is 4.93.
Good Sign:
Applied BioCode Corp stock PS Ratio (=4.94) is close to 1-year low of 4.63.
The historical rank and industry rank for Applied BioCode's PS Ratio or its related term are showing as below:
TPE:6598'
s PS Ratio Range Over the Past 10 Years
Min: 3.88 Med: 7.07 Max: 456.2
Current: 4.93
During the past 13 years, Applied BioCode's highest PS Ratio was 456.20. The lowest was 3.88. And the median was 7.07.
TPE:6598's PS Ratio is ranked worse than 67.95% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs TPE:6598: 4.93
During the past 12 months, the average Revenue per Share Growth Rate of Applied BioCode was 22.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 0.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 3.90% per year.
During the past 13 years, Applied BioCode's highest 3-Year average Revenue per Share Growth Rate was 88.70% per year. The lowest was -39.70% per year. And the median was 9.90% per year.
Back to Basics: PS Ratio
Applied BioCode (TPE:6598) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Applied BioCode PS Ratio Related Terms
Applied BioCode PS Ratio Historical Data
* Premium members only.
The historical data trend for Applied BioCode's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Applied BioCode's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Applied BioCode PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Applied BioCode's PS Ratio distribution charts can be found below:
* The bar in red indicates where Applied BioCode's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Applied BioCode's Share Price of today is NT$22.85. Applied BioCode's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$4.64.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Applied BioCode (TPE:6598) has a PS Ratio of 4.93 as of Jul. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Applied BioCode and its competitors. This is 30% below median its historical median of 7.07. Over the past decade, Applied BioCode's PS Ratio has ranged from 3.88 to 456.20. According to the industry distribution chart, Applied BioCode ranks #547 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 68%.
Is Applied BioCode's PS Ratio too high?
Applied BioCode's current PS Ratio of 4.93 is 30% below median its 10-year median of 7.07. Over the past 10 years, this metric has ranged from a low of 3.88 to a high of 456.20. The Medical Devices & Instruments industry median PS Ratio is 2.94. Applied BioCode's value of 4.93 is 67.7% above this industry median. Based on the distribution chart, Applied BioCode ranks #547 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Applied BioCode has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Applied BioCode's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Applied BioCode ranks #547 out of 805 companies for PS Ratio. This places Applied BioCode in the lower half of its industry. The industry median PS Ratio is 2.94. Applied BioCode's value of 4.93 is 67.7% above this benchmark. Historically, Applied BioCode's own PS Ratio has ranged from 3.88 to 456.20 over the past decade. While the company's 10-year median is 7.07 vs. the industry median of 2.94, Applied BioCode has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Applied BioCode's current PS Ratio of 4.93 is 67.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Applied BioCode and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Applied BioCode's current PS Ratio is 4.93, which is 30% below median its own 10-year median of 7.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Applied BioCode stock overvalued right now?
Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Fairly Valued. The stock's GF Value™ is NT$23.34, compared to a current price of NT$22.85 — trading 2.1% below its estimated fair value. The current PS Ratio is 4.93, which is 30% below median its 10-year median of 7.07 and 67.7% above the Medical Devices & Instruments industry median of 2.94. Applied BioCode's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current PS Ratio is 4.93 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Applied BioCode (TPE:6598) Overvalued in 2026?
Based on GuruFocus' analysis, Applied BioCode stock appears to be undervalued.
The current stock price of NT$22.85 is trading 2.1% below its estimated GF Value™ of NT$23.34.
GuruFocus considers Applied BioCode to be Fairly Valued.
Key valuation signals for TPE:6598:
PS Ratio: 4.93 (30% below median its 10-year median of 7.07)
GF Value™: NT$23.34 vs. price of NT$22.85 (2.1% below fair value)
Industry Position: 67.7% above the Medical Devices & Instruments median (#547 of 805)
No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
74GF Score
Get the complete analysis for TPE:6598
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6598 has been successfully added to your 
